Trexquant Investment LP Has $2.92 Million Stock Holdings in BioCryst Pharmaceuticals, Inc. $BCRX

Key Points

• Trexquant Investment LP reduced its stake in BioCryst Pharmaceuticals by 21.2%, leaving it with 389,392 shares valued at approximately $2.92 million.
• Insider trading activity saw Director Theresa Heggie sell 70,000 shares for around $595,700, decreasing her ownership by 51.72%.
• Analysts have a favorable outlook on BioCryst Pharmaceuticals, with nine rating it as a Buy and an average target price of $16.70.

Trexquant Investment LP trimmed its stake in shares of BioCryst Pharmaceuticals, Inc. (NASDAQ:BCRX - Free Report) by 21.2% during the first quarter, according to the company in its most recent disclosure with the Securities & Exchange Commission. The firm owned 389,392 shares of the biotechnology company's stock after selling 104,964 shares during the period. Trexquant Investment LP owned about 0.19% of BioCryst Pharmaceuticals worth $2,920,000 as of its most recent SEC filing.

A number of other hedge funds and other institutional investors have also made changes to their positions in the stock. Two Sigma Advisers LP raised its holdings in shares of BioCryst Pharmaceuticals by 14.6% during the fourth quarter. Two Sigma Advisers LP now owns 2,499,812 shares of the biotechnology company's stock worth $18,799,000 after acquiring an additional 318,800 shares during the period. Jupiter Asset Management Ltd. raised its holdings in shares of BioCryst Pharmaceuticals by 82.4% during the first quarter. Jupiter Asset Management Ltd. now owns 2,148,969 shares of the biotechnology company's stock worth $16,117,000 after acquiring an additional 971,040 shares during the period. Northern Trust Corp raised its holdings in shares of BioCryst Pharmaceuticals by 7.7% during the fourth quarter. Northern Trust Corp now owns 2,004,911 shares of the biotechnology company's stock worth $15,077,000 after acquiring an additional 143,986 shares during the period. Two Sigma Investments LP raised its holdings in shares of BioCryst Pharmaceuticals by 0.8% during the fourth quarter. Two Sigma Investments LP now owns 1,774,214 shares of the biotechnology company's stock worth $13,342,000 after acquiring an additional 13,406 shares during the period. Finally, Nuveen LLC acquired a new stake in shares of BioCryst Pharmaceuticals during the first quarter worth $10,677,000. 85.88% of the stock is currently owned by institutional investors and hedge funds.

BioCryst Pharmaceuticals Trading Down 1.9%

Shares of BCRX traded down $0.16 during midday trading on Tuesday, reaching $8.04. The stock had a trading volume of 473,311 shares, compared to its average volume of 3,684,539. The firm has a 50 day simple moving average of $8.51 and a 200-day simple moving average of $8.74. BioCryst Pharmaceuticals, Inc. has a one year low of $6.01 and a one year high of $11.31. The firm has a market cap of $1.69 billion, a PE ratio of -44.64, a P/E/G ratio of 1.88 and a beta of 1.13.

BioCryst Pharmaceuticals (NASDAQ:BCRX - Get Free Report) last announced its quarterly earnings data on Monday, August 4th. The biotechnology company reported $0.15 EPS for the quarter, beating analysts' consensus estimates of $0.03 by $0.12. The firm had revenue of $163.35 million during the quarter, compared to the consensus estimate of $149.59 million. During the same period last year, the business earned ($0.06) EPS. The business's revenue was up 49.5% on a year-over-year basis. As a group, research analysts forecast that BioCryst Pharmaceuticals, Inc. will post -0.36 EPS for the current fiscal year.

Wall Street Analysts Forecast Growth

A number of brokerages recently commented on BCRX. Wall Street Zen upgraded shares of BioCryst Pharmaceuticals from a "buy" rating to a "strong-buy" rating in a report on Saturday, July 26th. Royal Bank Of Canada reaffirmed an "outperform" rating and issued a $13.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, June 30th. Bank of America raised their target price on shares of BioCryst Pharmaceuticals from $13.00 to $15.00 and gave the company a "buy" rating in a research report on Tuesday, July 1st. Wedbush raised their target price on shares of BioCryst Pharmaceuticals from $16.00 to $18.00 and gave the company an "outperform" rating in a research report on Monday, June 30th. Finally, Needham & Company LLC reaffirmed a "buy" rating and issued a $17.00 target price on shares of BioCryst Pharmaceuticals in a research report on Monday, August 4th. Nine analysts have rated the stock with a Buy rating and one has issued a Hold rating to the company's stock. Based on data from MarketBeat, the stock presently has an average rating of "Moderate Buy" and an average target price of $16.70.

Insider Activity at BioCryst Pharmaceuticals

In other news, Director Theresa Heggie sold 70,000 shares of BioCryst Pharmaceuticals stock in a transaction dated Wednesday, August 13th. The shares were sold at an average price of $8.51, for a total value of $595,700.00. Following the completion of the transaction, the director owned 65,352 shares of the company's stock, valued at $556,145.52. This trade represents a 51.72% decrease in their position. The sale was disclosed in a legal filing with the SEC, which is available at this link. 5.10% of the stock is currently owned by company insiders.

BioCryst Pharmaceuticals Company Profile

BioCryst Pharmaceuticals, Inc, a biotechnology company, develops oral small-molecule and protein therapeutics to treat rare diseases. The company markets peramivir injection, an intravenous neuraminidase inhibitor for the treatment of acute uncomplicated influenza under the RAPIVAB, RAPIACTA, and PERAMIFLU names; and ORLADEYO, an oral serine protease inhibitor to treat hereditary angioedema.